CN Patent

CN111825606A — 一种伐度司他晶型及其制备方法

Assigned to Anlite Shanghai Pharmaceutical Technology Co ltd · Expires 2020-10-27 · 6y expired

What this patent protects

本发明涉及伐度司他新晶型及制备方法。具体地，本发明提供了{[5‑(3‑氯苯基)‑3‑羟基吡啶‑2‑羟基吡啶‑2‑羰基]氨基}乙酸(式I化合物)的新晶型及其制备方法。与现有技术相比，本发明的新晶型具有优异的晶型稳定性和机械稳定性等性能，适合大规模生产。

USPTO Abstract

本发明涉及伐度司他新晶型及制备方法。具体地，本发明提供了{[5‑(3‑氯苯基)‑3‑羟基吡啶‑2‑羟基吡啶‑2‑羰基]氨基}乙酸(式I化合物)的新晶型及其制备方法。与现有技术相比，本发明的新晶型具有优异的晶型稳定性和机械稳定性等性能，适合大规模生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN111825606A
Jurisdiction
CN
Classification
—
Expires
2020-10-27
Drug substance claim
No
Drug product claim
No
Assignee
Anlite Shanghai Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.